Antimicrobial Resistance Diagnostics Market – By Product Type, By Technology, By Pathogen Type, By End Use, Global Forecast, 2024 – 2032

Antimicrobial Resistance Diagnostics Market Size

The global antimicrobial resistance diagnostics market was valued at USD 4.4 billion in 2023 and is estimated to grow at a CAGR of over 6.3% from 2024 to 2032. The market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections, rising demand for personalized medicine, and surging advancements in diagnostic technology.
 

For example, according to the CDC, at least 2.8 million people in the U.S. are infected with antibiotic-resistant bacteria annually, leading to over 35,000 deaths. This escalating threat highlights the urgent need for accurate diagnostics to manage infections effectively, further driving market growth.
 

Moreover, advancements and innovations in molecular diagnostics, immunoassays, and next-generation sequencing (NGS) have improved the accuracy and speed of resistance detection. For instance, molecular diagnostics are particularly favored for their rapid results and high precision, which contributes to their dominance in the market. Furthermore, governments and health organizations increasingly recognize antimicrobial resistance (AMR) as a critical public health issue, leading to funding and initiatives to enhance diagnostic capabilities. In the U.S., for example, the National Action Plan for Combating Antibiotic-Resistant Bacteria emphasizes the importance of rapid diagnostic tests.
 

Antimicrobial resistance (AMR) threatens the effective prevention and treatment of a growing range of infections caused by bacteria, parasites, viruses, and fungi. Rapid diagnostic tests that identify drug-resistant bacteria, determine antimicrobial susceptibility, and distinguish viral from bacterial infections can guide effective treatment strategies. Additionally, rapid diagnostic tests can support epidemiological surveillance, as emerging resistant infectious agents and their transmission can be monitored.
 

Antimicrobial Resistance Diagnostic Market Trends

The rise in innovations in diagnostic technologies, including the introduction of polymerase chain reaction (PCR) and next-generation sequencing, has enabled rapid and accurate detection of resistant bacteria, further driving the growth of the antimicrobial resistance (AMR) diagnostic market. Moreover, the increasing shift towards point-of-care testing, which allows for immediate results and faster decision-making in treatment, is anticipated to boost demand for AMR diagnostics, thus propelling market growth.
 

For instance, in June 2023, Sysmex Corporation launched a testing system in Europe for the rapid detection of antimicrobial susceptibility. The system detects the presence or absence of bacteria and assesses antimicrobial effectiveness using urine samples from patients suspected of having urinary tract infections (UTIs). Consequently, various factors—such as rising infection rates, heightened public awareness, technological advancements, supportive government initiatives, and a growing emphasis on personalized medicine—are driving market growth.
 

Antimicrobial Resistance Diagnostic Market Analysis

Based on product type, the market is segmented into kits & reagents, and instruments & consumables. The kits & reagents segment dominated the market with USD 2.8 billion in 2023.
 

• Kits and reagents for antimicrobial resistance (AMR) diagnostics enable the early and accurate identification of resistant bacterial strains. This timely detection is essential for initiating effective treatments, as prompt diagnosis helps reduce the inappropriate use of antibiotics—a key factor contributing to the development of resistance.
   
• Additionally, national and international initiatives are driving increased demand for AMR diagnostic kits and reagents. The World Health Organization's Global Antimicrobial Resistance Surveillance System (GLASS) exemplifies these efforts by aiming to collect worldwide AMR data.
   
• Consequently, such programs create a substantial need for standardized diagnostic tools to ensure consistent and comparable results across different regions and healthcare systems.

Based on technology, the antimicrobial resistance diagnostic market is bifurcated into microbiology culture, immunoassay, polymerase chain reaction (PCR), next generation sequencing (NGS), mass spectrometry, rapid & point of care, and other technologies. The microbiology culture segment accounted for significant market share of 31.1% in 2023.
 

• Advancements in microbial culture technology have significantly enhanced the accuracy, speed, and specificity of resistant strain identification. Automated culture systems, such as the BD Phoenix and Vitek platforms, have reduced diagnostic turnaround times from days to hours.
   
• Such improvements have increased the reliability of culture-based diagnostics in identifying antibiotic-resistant bacteria, a factor anticipated to drive market growth.
   
• Additionally, antimicrobial resistance (AMR) poses a significant economic challenge, with projections indicating a potential global GDP loss of $100 trillion by 2050. Accurate diagnostics, particularly microbiology cultures, play a crucial role in mitigating costs associated with resistant infections.
   
• These diagnostic tools also contribute to improved treatment outcomes and help prevent prolonged hospital stays, thereby reducing the overall economic burden of AMR.
   

Based on pathogen type, the antimicrobial resistance diagnostic market is divided into drug-resistant streptococcus pneumoniae (DRSP), drug-resistant campylobacter (DRC), clostridium difficile (CD), drug-resistant Neisseria gonorrhoeae (DRNG), and other pathogen types. The clostridium difficile segment is expected to reach USD 2.3 billion by 2032.
 

• C. difficile is a leading cause of healthcare-associated infections (HAIs), especially among hospitalized patients and the elderly. With the aging global population and increased prevalence of comorbidities, infection rates are on the rise. According to the CDC, there are approximately 500,000 C. difficile infections per year in the United States, with a 20% recurrence rate.
   
• Furthermore, advanced technologies, such as next-generation sequencing (NGS) and AI-based diagnostics, are emerging, enabling a deeper understanding of C. difficile strains and resistance patterns. Although still in the early stages, these technologies promise to enhance diagnostic accuracy and provide insights into infection epidemiology.
   

Based on end use, the antimicrobial resistance diagnostic market is divided into hospitals & clinics, diagnostic laboratories, pharmaceutical & biotechnology companies, and other end users. The hospitals & clinics segment dominated the market with USD 1.8 billion in 2023.
 

• Hospitals and clinics are primary sites for AMR testing due to the high risk of exposure to resistant pathogens. Approximately 1 in 31 hospitalized patients in the U.S. suffers from HAIs, significantly increasing the need for AMR diagnostics to identify and manage these infections.
   
• Additionally, hospitals conduct a high volume of diagnostic tests, increasing the demand for rapid and accurate AMR diagnostics. Point-of-care testing and rapid diagnostics in hospital settings enable clinicians to initiate targeted treatments promptly, reducing the spread of resistant infections.

U.S. antimicrobial resistance diagnostic market is expected to grow at 6.2% CAGR, to reach USD 3.1 billion by 2032.
 

• The U.S. government has implemented initiatives such as the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) and the Antibiotic Resistance Solutions Initiative (ARSI) to enhance antimicrobial resistance (AMR) diagnostic capabilities.
   
• CARB aims to improve AMR diagnostics through technological advancements and provides grants and funding to diagnostic companies and research institutions, supporting market growth.
   
• Furthermore, the U.S. Department of Health and Human Services (HHS) has pledged substantial investments for AMR research, diagnostics, and the development of new antibiotics. In 2023 alone, the CDC’s AR Lab Network received increased funding to support regional testing for AMR pathogens, further propelling market growth.
   

Germany antimicrobial resistance diagnostic market is experiencing robust growth in the European market.
 

• Germany is seeing an increase in AMR cases, particularly with bacterial pathogens like Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae. For instance, in 2021, Klebsiella pneumoniae showed carbapenem resistance in 5.2% of cases, a relatively high rate compared to neighboring EU countries.
   
• Additionally, Germany faces substantial costs related to AMR infections. Healthcare-associated infections due to resistant pathogens contribute up to USD 1.5 billion annually in additional healthcare costs, fueling market growth.
   

The Asia Pacific antimicrobial resistance diagnostic market is witnessing substantial growth of 6.8% during the analysis period.
 

• The Chinese government’s healthcare reforms, such as Healthy China 2030, aim to make diagnostics more accessible and affordable, facilitating the growth of the AMR diagnostics market.
   
• Moreover, China is adopting advanced molecular diagnostics like PCR-based assays and next-generation sequencing (NGS), which provide rapid and accurate identification of AMR strains, further contributing to market growth.
   

The Brazil market is experiencing robust growth in Latin America.
 

• Brazil’s National Action Plan on AMR includes guidelines for the surveillance of antimicrobial use and resistance, with mandatory reporting and data sharing by healthcare institutions.
   
• Additionally, according to the Brazilian Association of Diagnostic Medicine, rapid diagnostic tests for infections have increased by 30% annually, driven in part by the urgent need for real-time identification of resistant bacteria.
   

The Saudi Arabia antimicrobial resistance diagnostic market is witnessing substantial growth during the analysis period.
 

• The Saudi government is committed to addressing AMR through regulatory frameworks and public health campaigns. The emphasis on early detection and intervention for managing resistant infections, supported by various health authorities, is fostering market growth.
   
• Additionally, increasing awareness about the consequences of AMR among healthcare providers, policymakers, and the public is driving demand for diagnostics. Educational initiatives promoting appropriate antibiotic use and improved diagnostic practices are also becoming more prevalent.
   

Antimicrobial Resistance Diagnostic Market Share

The global antimicrobial resistance (AMR) diagnostic market is highly competitive, with key players actively innovating to address the escalating AMR crisis. Major companies offer advanced diagnostic solutions, including molecular diagnostics and point-of-care testing. These companies invest significantly in research and development to improve diagnostic accuracy, reduce test turnaround times, and enhance pathogen detection capabilities.
 

Strategic collaborations and partnerships are common, as companies aim to leverage technological advancements like next-generation sequencing (NGS) and PCR-based assays to expand their product portfolios. Government initiatives and regulatory support further propel market players to develop effective AMR diagnostic tools. Additionally, emerging players focus on regional markets, where the demand for AMR diagnostics is rising, particularly in Asia Pacific and Latin America, as governments there increase investments in healthcare infrastructure to combat AMR.
 

Antimicrobial Resistance Diagnostic Market Companies

Prominent players operating in the antimicrobial resistance diagnostic industry include:

• Abbott Laboratories
• Accelerated Diagnostics, USA
• Alifax
• Bio-Rad Laboratories
• BioMerieux
• Beckman Coulter
• Becton, Dickinson and Company
• F. Hoffmann-La Roche
• GeneFluidics
• Molsid
• Thermo Fisher Scientific
• Vela Diagnostics
   

Antimicrobial Resistance Diagnostic Industry News:

• In In October 2024, FIND and the Kingdom of Saudi Arabia announced the convening of a high-level side event focused on closing gaps in diagnostics to prevent antimicrobial resistance (AMR). This initiative aims to tackle AMR and is expected to expand the organization's reach into untapped economies.
   
• In July 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, along with the life sciences company Evotec SE and bioMérieux, announced a joint venture to develop the next generation of antimicrobials and actionable diagnostics to combat AMR. This collaboration helped the company broaden its product offerings for AMR diagnosis.
   

The antimicrobial resistance diagnostic market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Kits & reagents
• Instruments & consumables

Market, By Technology

• Microbiology culture
• Immunoassay
• Polymerase chain reaction (PCR)
• Next generation sequencing (NGS)
• Mass spectrometry
• Rapid & point of care
• Other technologies

Market, By Pathogen Type

• Drug-resistant streptococcus pneumoniae (DRSP)
• Drug-resistant campylobacter (DRC)
• Clostridium difficile (CD)
• Drug-resistant Neisseria gonorrhoeae (DRNG)
• Other pathogen types

Market, By End Use

• Hospitals & clinics
• Diagnostic laboratories
• Pharmaceutical & biotechnology companies
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE